Rise and fall of an anti-MUC1 specific antibody

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Thie, Holger ^a,e   Toleikis, Lars ^a,f   Li, Jiandong ^a,g   Von Wasielewski, Reinhard ^b   Bastert, Gunther ^c,h   Schirrmann, Thomas ^a   Esteves, Isabel Tourais ^d   Behrens, Christian K ^d   Fournes, Bénédict ^d   Fournier, Nathalie ^d   de Romeuf, Christophe ^d   Hust, Michael ^a   Dübel, Stefan ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d LFB Biotechnologies Research Department   (France)

^e MILTENYI BIOTEC GMBH   (Germany)

^f MERCK KGAA   (Germany)

^g National Institute for Viral Disease Control and Prevention   (China)

^h UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER ANTIBODY; IMMUNOGLOBULIN G; MUCIN 1; MUCIN 1 ANTIBODY; PACLITAXEL; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; EPITOPE; MONOCLONAL ANTIBODY; PEPTIDE LIBRARY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ISOLATION; ANTIBODY LIBRARY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER SURVIVAL; CONTROLLED STUDY; DIMERIZATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERNALIZATION; MOUSE; MUTAGENESIS; NONHUMAN; PHAGE DISPLAY; SURVIVAL RATE; TARGET CELL; TUMOR XENOGRAFT; VACCINE FAILURE; ANIMAL; BREAST TUMOR; DRUG SCREENING; IMMUNOLOGY; TUMOR CELL LINE;

MAMMALIA;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; EPITOPES; FEMALE; HUMANS; MICE; MUCIN-1; PEPTIDE LIBRARY; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79251582198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015921     Document Type: Article

References (108)

1. McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348: 552-554.
2. Clackson T, Hoogenboom HR, Griffiths AD, Winter G (1991) Making antibody fragments using phage display libraries. Nature 352: 624-628.
3. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, et al. (1991) Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 19: 4133-4137.
4. Breitling F, Dübel S, Seehaus T, Klewinghaus I, Little M (1991) A surface expression vector for antibody screening. Gene 104: 147-153.
5. Hust M, Meyer T, Voedisch B, Rülker T, Thie H, et al. (2010) A human scFv antibody generation pipeline for proteome research. J Biotechnol, Available at: http://www.ncbi.nlm.nih.gov/pubmed/20883731. Accessed 7 November 2010.
6. Dübel S, Stoevesandt O, Taussig MJ, Hust M (2010) Generating recombinant antibodies to the complete human proteome. Trends Biotechnol 28: 333-339.
7. Schofield DJ, Pope AR, Clementel V, Buckell J, Chapple SD, et al. (2007) Application of phage display to high throughput antibody generation and characterization. Genome Biol 8: R254.
8. Pelat T, Hust M, Hale M, Lefranc M, Dübel S, et al. (2009) Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol 9: 60.
9. Cardoso DF, Nato F, England P, Ferreira ML, Vaughan TJ, et al. (2000) Neutralizing human anti crotoxin scFv isolated from a nonimmunized phage library. Scand J Immunol 51: 337-344.
10. Williamson P, Matthews R (1999) Development of neutralising human recombinant antibodies to pertussis toxin. FEMS Immunol Med Microbiol 23: 313-319.
11. Kirsch M, Hülseweh B, Nacke C, Rülker T, Schirrmann T, et al. (2008) Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol 8: 66.
12. Sun L, Lu X, Li C, Wang M, Liu Q, et al. (2009) Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS ONE 4: e5476.
13. Meyer T, Stratmann-Selke J, Meens J, Schirrmann T, Gerlach GF, et al. (2011) Isolation of scFv fragments specific to OmpD of Salmonella Typhimurium. Vet Microbiol 147: 162-169.
14. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, et al. (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222: 581-97.
15. Dübel S (2007) Recombinant therapeutic antibodies. Appl Microbiol Biotechnol 74: 723-729.
16. Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23: 1105-16.
17. Thie H, Meyer T, Schirrmann T, Hust M, Dübel S (2008) Phage display derived therapeutic antibodies. Curr Pharm Biotechnol 9: 439-446.
18. Gram H, Marconi LA, Barbas CF, Collet TA, Lerner RA, et al. (1992) In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc Natl Acad Sci USA 89: 3576-3580.
19. Hawkins RE, Russell SJ, Winter G (1992) Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol 226: 889-896.
20. Jones SE (2008) Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 8: 224-33.
21. Bafna S, Kaur S, Batra SK (2010) Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 29: 2893-2904.
22. Mukherjee P, Ginardi AR, Madsen CS, Tinder TL, Jacobs F, et al. (2001) MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J 18: 931-942.
23. Albrecht H, Denardo GL, Denardo SJ (2007) Development of anti-MUC1 discFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. Q J Nucl Med Mol Imaging 51: 304-313.
24. Jonckheere N, Van Seuningen I (2010) The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers. Biochimie 92: 1-11.
25. Patton S, Gendler SJ, Spicer AP (1995) The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1241: 407-423.
26. Zotter S, Hageman PC, Lossnitzer A, van den Tweel J, Hilkens J, et al. (1988) Monoclonal antibodies to epithelial sialomucins recognize epitopes at different cellular sites in adenolymphomas of the parotid gland. Int J Cancer 3(Suppl): 38-44.
27. Gendler SJ, Burchell JM, Duhig T, Lamport D, White R, et al. (1987) Cloning of partial cDNA encoding differentiation and tumor-associated mucinglycoproteins expressed by human mammary epithelium. Proc Natl Acad Sci USA 84: 6060-6064.
28. Carraway KL, Ramsauer VP, Haq B, Carothers Carraway CA (2003) Cell signaling through membrane mucins. Bioessays 25: 66-71.
29. Parry G, Beck JC, Moss L, Bartley J, Ojakian GK (1990) Determination of apical membrane polarity in mammary epithelial cell cultures: the role of cell cell, cell-substratum, and membrane-cytoskeleton interactions. Exp Cell Res 188: 302-311.
30. Spicer AP, Parry G, Patton S, Gendler SJ (1991) Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J Biol Chem 266: 15099-15109.
31. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, et al. (1990) Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265: 15286-15293.
32. Burchell J, Taylor-Papadimitriou J, Boshell M, Gendler S, Duhig T (1989) A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int J Cancer 44: 691-696.
33. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J (1988) A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263: 12820-12823.
34. Swallow DM, Gendler S, Griffiths B, Corney G, Taylor-Papadimitriou J, et al. (1987) The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature 328: 82-84.
35. Hanisch FG, Müller S (2000) MUC1: the polymorphic appearance of a human mucin. Glycobiology 10: 439-449.
36. Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, et al. (1988) Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci USA 85: 2320-2323.
37. Hanisch FG, Peter-Katalinic J, Egge H, Dabrowski U, Uhlenbruck G (1990) Structures of acidic O-linked polylactosaminoglycans on human skim milk mucins. Glycoconj J 7: 525-543.
38. Hanisch FG, Uhlenbruck G, Peter-Katalinic J, Egge H, Dabrowski J, et al. (1989) Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyllactosamine backbones with Gal beta(1-4)GlcNAc beta(1-6) repeating units. J Biol Chem 264: 872-883.
39. Hull SR, Bright A, Carraway KL, Abe M, Hayes DF, et al. (1989) Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun 1: 261-267.
40. Lillehoj EP, Kim BT, Kim KC (2002) Identification of Pseudomonas aeruginosa flagellin as an adhesin for Muc1 mucin. Am J Physiol Lung Cell Mol Physiol 282: L751-L756.
41. Vimal DB, Khullar M, Gupta S, Ganguly NK (2000) Intestinal mucins: the binding sites for Salmonella typhimurium. Mol Cell Biochem 204: 107-117.
42. Gendler SJ, Spicer AP (1995) Epithelial mucin genes. Annu Rev Physiol 57: 607-634.
43. Lagow E, DeSouza MM, Carson DD (1999) Mammalian reproductive tract mucins. Hum Reprod Update 5: 280-292.
44. Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL, et al. (1981) Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 28: 17-21.
45. Danielczyk A, Stahn R, Faulstich D, Löffler A, Märten A, et al. (2006) PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol. Immunother 55: 1337-1347.
46. Hilkens J, Kroezen V, Bonfrer JM, De Jong-Bakker M, Bruning PF (1986) MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res 46: 2582-2587.
47. Safi F, Kohler I, Röttinger E, Beger H (1991) The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 68: 574-582.
48. Lloyd KO, Burchell J, Kudryashov V, Yin BW, Taylor-Papadimitriou J (1996) Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem 271: 33325-33334.
49. Singh R, Bandyopadhyay D (2007) MUC1: a target molecule for cancer therapy. Cancer Biol Ther 6: 481-486.
50. Schoonooghe S, Burvenich I, Vervoort L, De Vos F, Mertens N, et al. (2010) PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1. Protein Eng Des Sel 23: 721-728.
51. Verhoeyen ME, Saunders JA, Price MR, Marugg JD, Briggs S, et al. (1993) Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody. Immunology 78: 364-370.
52. Fan X, Karsten U, Goletz S, Cao Y (2010) Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol Res Pract, Available at: http://www.ncbi.nlm.nih.gov/pubmed/20400237. Accessed 16 June 2010.
53. Price MR, Rye PD, Petrakou E, Murray A, Brady K, et al. (1998) Summaryreport on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996. Tumour Biol 19(Suppl 1): 1-20.
54. Henderikx P, Kandilogiannaki M, Petrarca C, von Mensdorff-Pouilly S, Hilgers JH, et al. (1998) Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res 58: 4324-4332.
55. Henderikx P, Coolen-van Neer N, Jacobs A, van der Linden E, Arends J, et al. (2002) A human immunoglobulin G1 antibody originating from an in vitroselected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized. Am J Pathol 160: 1597-1608.
56. Welschof M, Terness P, Kolbinger F, Zewe M, Dübel S, et al. (1995) Amino acid sequence based PCR primers for amplification of rearranged human heavy and light chain immunoglobulin variable region genes. J Immunol Methods 179: 203-214.
57. Welschof M, Terness P, Kipriyanov SM, Stanescu D, Breitling F, et al. (1997) The antigen-binding domain of a human IgG-anti-F(ab')2 autoantibody. Proc Natl Acad Sci USA 94: 1902-1907.
58. Mollova S, Retter I, Hust M, Dübel S, Mü ller W (2010) Analysis of single chain antibody sequences using the VBASE2 Fab analysis tool. In: Antibody Engineering. Heidelberg/New York: Springer Verlag. pp 3-10.
59. Pelat T, Hust M, Laffly E, Condemine F, Bottex C, et al. (2007) High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 51: 2758-2764.
60. Schütte M, Thullier P, Pelat T, Wezler X, Rosenstock P, et al. (2009) Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS ONE 4: e6625.
61. Abhinandan KR, Martin ACR (2007) Analyzing the ''degree of humanness'' of antibody sequences. J Mol Biol 369: 852-862.
62. Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc M, et al. (2008) Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 384: 1400-1407.
63. Beatty PL, Narayanan S, Gariépy J, Ranganathan S, Finn OJ (2010) Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila Pa) 3: 438-446.
64. Kurtenkov O, Klaamas K, Mensdorff-Pouilly S, Miljukhina L, Shljapnikova L, et al. (2007) Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 46: 316-323.
65. Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, et al. (2008) A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 6: 955-964.
66. Pelat T, Hust M, Thullier P (2009) Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. Mini Rev Med Chem 9: 1633-1638.
67. Kim SJ, Jang MH, Ahn HJ, Kim JH, Lim JH, et al. (2008) Selection of an affinity-matured antibody against a defined epitope by phage display of an immune antibody library. J Immunol Methods 329: 176-183.
68. Thie H, Voedisch B, Dübel S, Hust M, Schirrmann T (2009) Affinity maturation by phage display. Methods Mol Biol 525: 309-322.
69. Irving RA, Kortt AA, Hudson PJ (1996) Affinity maturation of recombinant antibodies using E. coli mutator cells. Immunotechnology 2: 127-143.
70. Low NM, Holliger PH, Winter G (1996) Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J Mol Biol 260: 359-368.
71. Yau KYF, Dubuc G, Li S, Hirama T, Mackenzie CR, et al. (2005) Affinity maturation of a V(H)H by mutational hotspot randomization. J Immunol Methods 297: 213-224.
72. Zhao X, Chen W, Yang Z, Li J, Zhang S, et al. (2009) Selection and affinity maturation of human antibodies against rabies virus from a scFv gene library using ribosome display. J Biotechnol 144: 253-258.
73. Wang Z, Kim G, Woo J, Liu YY, Mathias A, et al. (2007) Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv. Bioconjug Chem 18: 947-955.
74. Park SG, Lee JS, Je EY, Kim IJ, Chung JH, et al. (2000) Affinity maturation of natural antibody using a chain shuffling technique and the expression of recombinant antibodies in Escherichia coli. Biochem Biophys Res Commun 275: 553-557.
75. Barderas R, Desmet J, Timmerman P, Meloen R, Casal JI (2008) Affinity maturation of antibodies assisted by in silico modeling. Proc Natl Acad Sci USA 105: 9029-9034.
76. Karanikas V, Patton K, Jamieson G, Pietersz G, McKenzie I (1998) Affinity of antibodies to MUC1 antigens. Tumour Biol 19(Suppl 1): 71-78.
77. Blockzjil A, Nilsson K, Nilsson O (1998) Epitope characterization of MUC1 antibodies. Tumour Biol 19(Suppl 1): 46-56.
78. Briggs S, Price MR, Tendler SJ (1993) Fine specificity of antibody recognition of carcinoma-associated epithelial mucins: antibody binding to synthetic peptide epitopes. Eur J Cancer 29A: 230-237.
79. Deshpapnde S (1996) Enzyme immunoassays from concept to product development. New York: Chapman & Hall, International Thompson Publishing.
80. Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, et al. (2010) Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 23: 115-127.
81. Arndt KM, Müller KM, Plückthun A (1998) Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry 37: 12918-12926.
82. Arndt MAE, Krauss J, Rybak SM (2004) Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers. FEBS Lett 578: 257-261.
83. Lee YC, Boehm MK, Chester KA, Begent RHJ, Perkins SJ (2002) Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy. J Mol Biol 320: 107-127.
84. Krebs B, Rauchenberger R, Reiffert S, Rothe C, Tesar M, et al. (2001) Highthroughput generation and engineering of recombinant human antibodies. J Immunol Methods 254: 67-84.
85. Muzard J, Bouabdelli M, Zahid M, Ollivier V, Lacapere JJ, et al. (2009) Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro. FEBS J 276: 4207-4222.
86. Skrlj N, Serbec VC, Dolinar M (2010) Single-chain Fv antibody fragments retain binding properties of the monoclonal antibody raised against peptide P1 of the human prion protein. Appl Biochem Biotechnol 160: 1808-1821.
87. Ferreira CSM, Cheung MC, Missailidis S, Bisland S, Gariépy J (2009) Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res 37: 866-876.
88. Pericleous LM, Richards J, Epenetos AA, Courtenay-Luck N, Deonarain MP (2005) Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1. Br J Cancer 93: 1257-1266.
89. Pietersz GA, Wenjun L, Krauer K, Baker T, Wreschner D, et al. (1997) Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy. Cancer Immunol. Immunother 44: 323-328.
90. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2007) Immunotoxin treatment of cancer. Annu Rev Med 58: 221-237.
91. Gerber H, Senter PD, Grewal IS (2009) Antibody drug-conjugates targeting the tumor vasculature: Current and future developments. MAbs 1: 247-253.
92. Teicher BA (2009) Antibody-drug conjugate targets. Curr Cancer Drug Targets 9: 982-1004.
93. Huang X, Bennett M, Thorpe PE (2004) Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostatespecific membrane antigen. Prostate 61: 1-11.
94. Kuroda K, Liu H, Kim S, Guo M, Navarro V, et al. (2010) Saporin toxinconjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. Prostate 70: 1286-1294.
95. Zielinski R, Lyakhov I, Jacobs A, Chertov O, Kramer-Marek G, et al. (2009) Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother 32: 817-825.
96. Trahtenherts A, Benhar I (2009) An internalizing antibody specific for the human asialoglycoprotein receptor. Hybridoma (Larchmt) 28: 225-233.
97. Schirrmann T, Krauss J, Arndt MAE, Rybak SM, Dübel S (2009) Targeted therapeutic RNases (ImmunoRNases). Expert Opin Biol Ther 9: 79-95.
98. Menzel C, Schirrmann T, Konthur Z, Jostock T, Dübel S (2008) Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood 111: 3830-3837.
99. Schirrmann T, Hust M (2010) Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol Biol 651: 177-209.
100. Hust M, Toleikis L, Dübel S (2007) Antibody phage display. In: Handbook of therapeutic antibodies. Weinheim: Wiley-VCH. pp 45-68.
101. von Wasielewski R, Mengel M, Gignac S, Wilkens L, Werner M, et al. (1997) Tyramine amplification technique in routine immunohistochemistry. J Histochem Cytochem 45: 1455-1459.
102. Hust M, Jostock T, Menzel C, Voedisch B, Mohr A, et al. (2007) Single chain Fab (scFab) fragment. BMC Biotechnol 7: 14.
103. Sambrook J, Russell D (2001) Molecular cloning: a laboratory manual. 3. ed. New York: Cold Spring Harbor Laboratory Press.
104. Hust M, Dübel S, Schirrmann T (2007) Selection of recombinant antibodies from antibody gene libraries. Methods Mol Biol 408: 243-55.
105. Hust M, Steinwand M, Al-Halabi L, Helmsing S, Schirrmann T, et al. (2009) Improved microtitre plate production of single chain Fv fragments in Escherichia coli. N Biotechnol 25: 424-428.
106. Dübel S, Breitling F, Klewinghaus I, Little M (1992) Regulated secretion and purification of recombinant antibodies in E. coli. Cell Biophys 21: 69-79.
107. Frank R (1992) Spot-Synthesis: An easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron 48: 9217-9232.
108. Frank R (2002) The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports-principles and applications. J Immunol Methods 267: 13-26.